Skip to main content

Table 2 RR and 95% CI of complications during gastrointestinal endoscopy

From: Efficacy and safety of esketamine for sedation among patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis

Subgroup

Complications

Control

Number of studies

Results of heterogeneity test

Meta analysis results

P value

I2

MD (95% CI)

P value

(A) injection pain

NS group

4

0.12

48%

0.20(0.08,0.49)

0.0004

(B) body movement

NS group

4

0.15

44%

0.76(0.65,0.90)

0.001

opioids group

2

0.64

0%

-0.11(0.21, -0.00)

0.05

(C) hypotension

NS group

6

0.006

69%

0.31(0.22,0.43)

0.003

opioids group

3

0.47

0%

-0.14(-0.21, -0.06)

0.0002

(D) respiratory depression

NS group

6

0.29

19%

0.33(0.19,0.58)

0.0001

opioids group

4

 < 0.001

86%

-0.15(-0.29, -0.00)

0.05

(E)nausea or vomiting

NS group

5

0.40

1%

0.78(0.30,2.04)

0.61

opioids group

4

 < 0.001

90%

-0.18(-0.41,0.04)

0.11

(F)Hypoxemia

NS group

3

1.05

47%

1.05(0.68,1.62)

0.84

opioids group

2

0.33

0%

-0.00(-0.06,0.06)

0.94

(G) hypertension

opioids group

3

0.07

62%

-0.04(-0.13,0.05)

0.42

(H)bradycardia

NS group

3

0.54

0%

0.71(0.14,3.66)

0.68

opioids group

3

0.06

64%

-0.01(-0.10,0.08)

0.85

(I)tachycardia

opioids group

2

0.50

0%

0.03(-0.04,0.10)

0.40

(J)delirium

NS group

2

0.11

61%

3.29(0.61,17.83)

0.17

(K)dizziness

NS group

6

0.99

0%

1.38(0.94,2.02)

0.10

(L) Visual disturbance

NS group

3

0.56

0%

5.84(1.88,18.20)

0.002